Diffuse Hemispheric Glioma, H3 G34-Mutant

Diffuse Hemispheric Glioma, H3 G34-Mutant — Trials · CancerIndex

Clinical trials

Registered studies

9 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 8
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: Institute of Cancer Research, United Kingdom
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06632236	5G-EMERALD: Amivantamab in Malignant Brain Tumours(5G-EMERALD)	active not recruiting	Phase 1	12	Institute of Cancer Research, United KingdomOTHER	1	Aug 17, 2026	clinicaltrials
NCT06342908	A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma	active not recruiting	Phase 1	6	Jonsson Comprehensive Cancer CenterOTHER	1	Feb 17, 2026